WGCNA generated strong correlations between the presence of SCFAs and a normal healthy GM, supporting Botticelli et al.’s hypothesis [17], and therefore it is potentially possible to consider SCFAs as biomarkers of anti-PD1 therapy response in NSCLC patients. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.